Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17283080 | 0.88 | SMN1; SMN2 (0.59) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10668976 | 0.84 | MAPT (0.67) | SMN1; SMN2KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL11117622 | 0.84 | MAPT (0.67) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL9477980 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL9475525 | 0.83 | POLB (0.62) | NPC1RAB9ASMN1; SMN2HPGDGALR3 | |
| SCHEMBL11245223 | 0.83 | HPGD (0.80) | SMN1; SMN2KDM4EHSD17B10HPGDGALR3 | |
| SCHEMBL10419778 | 0.80 | HPGD (0.55) | SMN1; SMN2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL9476992 | 0.80 | CA5A (0.53) | SMN1; SMN2ALDH1A1HPGDGALR3CYP3A4 | |
| SCHEMBL16179036 | 0.79 | HSD17B10 (0.58) | SMN1; SMN2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL7265939 | 0.77 | SMN1; SMN2 (0.72) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050994-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | THE JOHNS HOPKINS UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-20180050994-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | THE JOHNS HOPKINS UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-9771335-B2 | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771335-B2 | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017147379-A1 | PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-GATED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017023739-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023739-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029382-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | AES GLOBAL HOLDINGS, PTE. LTD. (SG) | 2017-02-02 | — | — | US | disclosed |
| US-20170029382-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | AES GLOBAL HOLDINGS, PTE. LTD. (SG) | 2017-02-02 | — | — | US | disclosed |
| US-9505727-B2 | Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505727-B2 | Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150368211-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | UNIV JOHNS HOPKINS (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368211-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | UNIV JOHNS HOPKINS (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150336904-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | UNIV JOHNS HOPKINS (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336904-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | UNIV JOHNS HOPKINS (US) | 2015-11-26 | — | — | US | disclosed |
| WO-2014120994-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120994-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
| US-5204353-A | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith | CIBA-GEIGY CORPORATION (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0288431-B1 | 3H-1,2,3-triazolo[4,5-d]pyrimidines | CIBA-GEIGY AG (CH) | 1992-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029382-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | SCN1A, HVCN1, SCN1B | NPC1 1737/4885RAB9A 1001/4885SMN1; SMN2 843/4885 |
| US-20150368211-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | SCN1A, SCN1B, SCN3A | NPC1 999/4885RAB9A 1507/4885SMN1; SMN2 291/4885 |
| US-20180050994-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | SCN1A, SCN1B, CACNA1S | NPC1 1312/4885RAB9A 1828/4885SMN1; SMN2 269/4885 |
| US-20150336904-A1 | RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | HVCN1, SCN1A, HCN1 | NPC1 1703/4885RAB9A 763/4885SMN1; SMN2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.